HSBC has issued a “Reduce” rating on Global Health (Medanta), with a target price of ₹990. The bank acknowledges Medanta’s ongoing efforts to boost growth through investments in new hospital beds, recruitment of doctors, and expansion of clinical specialties.
However, HSBC warns that the current stock price may not fully reflect the challenges the company faces in its key Lucknow market, along with execution risks tied to its new hospital projects. A potential upside to this outlook could come from stronger-than-expected performance at Medanta’s Lucknow facility.
